Gosset Ownership
Public
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Ventyx Biosciences General Information
Ventyx has multiple programs in Phase 2 clinical trials. Their NLRP3 inhibitors VTX2735 and VTX3232 are in Phase 2 for recurrent pericarditis and neurodegenerative/cardiometabolic diseases respectively. Their inflammatory bowel disease portfolio includes tamuzimod (S1P1R modulator) and VTX958 (TYK2 inhibitor), both of which have completed Phase 2 clinical trials.
Contact Information
Website
Primary Industry
Biotech
Corporate Office
San Diego, California
United States
United States
Drug Pipeline
VTX2735
Phase 2Key Partnerships
Sanofi ($27 million strategic investment in September 2024)
Ventyx Biosciences Funding
| Deal Type | Date | Amount | Status | Stage |
|---|---|---|---|---|
| Investment | Sep 24, 2024 | $27.0M | Completed | Phase 2 |
To view Ventyx Biosciences's complete valuation and funding history, request access »
Ventyx Biosciences Financial Metrics
Market Cap
$1004.5M
Enterprise Value
$821.9M